

# Association Study of the Estrogen Receptor I Gene (*ESR1*) in Anorexia Nervosa and Eating Disorders: No Replication Found

Margarita C.T. Slof-Op 't Landt, PhD<sup>1,2,3\*</sup>  
 Eric F. van Furth, PhD<sup>1,4</sup>  
 Ingrid Meulenbelt, PhD<sup>2</sup>  
 Meike Bartels, PhD<sup>3</sup>  
 Jouke Jan Hottenga, PhD<sup>3</sup>  
 P. Eline Slagboom, PhD<sup>2,5</sup>  
 Dorret I. Boomsma, PhD<sup>3</sup>

## ABSTRACT

**Objective:** The female preponderance and onset around puberty in the majority of eating disorders (EDs) suggest that sex hormones, like estrogens, may be involved in the onset of these disorders. An eight-SNP haplotype at the estrogen receptor I (*ESR1*) gene was found to be associated with anorexia nervosa (AN) (Versini et al., *Neuropsychopharmacology*, 35, 1818–1825, 2010) and three SNPs from this haplotype (rs726281, rs2295193, and rs3798577) were associated with AN and/or EDs. Our objective was to replicate these findings in an independent cohort of 520 patients with an eating disorder, of whom 244 had AN (142 restricting type) from the GenED study and 2,810 random women from the Netherlands Twin Registry.

**Method:** The frequencies of the eight-SNP haplotype and three *ESR1* SNPs were compared between patients with an eating disorder, with AN (restricting type), with bulimia nervosa (BN), and the control women.

**Results:** Neither the haplotype nor the three *ESR1* SNPs were associated with EDs, BN, AN, or restricting type AN.

**Discussion:** Despite sufficient statistical power, the associations reported by Versini et al. (*Neuropsychopharmacology*, 35, 1818–1825, 2010) were not replicated. © 2013 Wiley Periodicals, Inc.

**Keywords:** estrogen; eating disorders; anorexia nervosa; genetic association; *ESR1*

(*Int J Eat Disord* 2014; 47:211–214)

## Introduction

The clear sex difference in eating disorders (EDs),<sup>1</sup> together with the age of onset around puberty for most EDs,<sup>2,3</sup> indicates that sex hormones, like estrogens, might be involved in the onset of EDs. Estradiol activates estrogen receptors  $\alpha$  and  $\beta$ , regulate transcriptional activation,<sup>4</sup> and also appear to be involved in the regulation (inhibition) of food intake.<sup>5,6</sup> The estrogen receptor I (*ESR1*) and *ESR2* genes, which respectively encode estrogen receptor

$\alpha$  and  $\beta$ , are expressed in several tissues throughout the body including the brain.<sup>4</sup>

Several *ESR1* and *ESR2* polymorphisms have been tested for association with EDs.<sup>7–10</sup> Rosekranz et al.<sup>8</sup> did not find an association between *ESR2* and anorexia (AN) or bulimia nervosa (BN), whereas two other studies did find associations between common *ESR2* polymorphisms and AN<sup>9</sup> or BN.<sup>10</sup> Recently, a large family-based association study examined common genetic variation at the *ESR1* and *ESR2* genes in relation to AN.<sup>7</sup> A haplotype of eight *ESR1* SNPs was associated with AN restricting type (OR = 3.1,  $p < 6 \times 10^{-6}$ ). In addition, three SNPs from this haplotype were associated with AN and/or EDs. A significant overtransmission was detected between AN and *ESR1* rs726281 (OR = 1.5,  $p < .02$ ) and rs2295193 (OR = 1.4,  $p < .02$ ). In addition, rs3798577 was associated with restricting type AN (OR = 1.6,  $p < .02$ ) and with EDs in a population-based sample of 693 women ( $p < .008$ ).

Because replication is essential to identify robust genetic associations, the current study tried to replicate the findings from this previous study.<sup>7</sup> The haplotype of the eight *ESR1* SNPs and the three separate *ESR1* SNPs were tested for association in

Accepted 24 October 2013

\*Correspondence to: Margarita C.T. Slof-Op 't Landt, Center for Eating Disorders Ursula, PO Box 422, 2260 AK Leidschendam, The Netherlands. E-mail: r.optlandt@centrummeetstoornissen.nl

<sup>1</sup> Center for Eating Disorders Ursula, Leidschendam, The Netherlands

<sup>2</sup> Leiden University Medical Centre, Molecular Epidemiology Section (Department of Medical Statistics), Leiden, The Netherlands

<sup>3</sup> Department of Biological Psychology, VU University, Amsterdam, The Netherlands

<sup>4</sup> Leiden University Medical Centre, Department of Psychiatry, Leiden, The Netherlands

<sup>5</sup> Netherlands Consortium for Healthy Ageing, Leiden University Medical Center, The Netherlands

Published online 26 November 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/eat.22228

© 2013 Wiley Periodicals, Inc.

520 patients with an ED, of whom 244 patients had AN (142 restricting type) and 143 had BN from the GenED study, and 2,810 random control women from the Netherlands Twin Registry (NTR).

## Method

### Participants

Five hundred twenty female patients with a DSM-IV ED diagnosis participated in the GenED study.<sup>11</sup> This study was approved by the committee for mental health institutions in the Netherlands (METiGG). All participants gave written informed consent. The majority of patients ( $n = 244$ ) had AN (142 restricting, 102 binge-eating/purging type), 143 had BN, and 133 patients had an ED not otherwise specified. Eighty-three percent of the patients with AN, 76% of the patients with BN, and 95% of the patients with an ED not otherwise specified had a current ED diagnoses, the remaining patients had a lifetime diagnoses.

The NTR collects data on multiples (twins or triplets) and their family members in longitudinal survey studies.<sup>12,13</sup> Subgroups have provided DNA samples. Data and DNA collection were approved by the ethics committee of the VU University. In the current study, 2,810 unrelated women, not screened for EDs, were drawn from the NTR. For 365 women direct *ESR1* genotyping was performed. For the remaining 2,445 women imputed *ESR1* genotype data from previous GWA studies<sup>12,13</sup> were available. Both control and patient groups were of European descent.

### Genotype Measurements

Eight *ESR1* SNPs (rs726281, rs3020407, rs17081994, rs2982712, rs3020371, rs2228480, rs3798577, rs2295193) were genotyped by mass spectrometry (the homogeneous MassARRAY system; Sequenom, San Diego, CA) using standard conditions in the patients and 365 control women.

In the majority of the control women, SNPs were imputed by SNPtest (version 2, merge release 5). As a quality control measure the  $r^2$  for the imputation was calculated, the  $r^2$  ranged between .97 and .99 for all SNPs, except for rs726281 and rs3020407 for which an  $r^2$  of .93 and .89 was found respectively. As an additional quality control step, the correlation between the genotyped and imputed SNPs was calculated in the 365 control women. The correlations for rs726281 and rs3020407 were moderate, .83 and .66 respectively, for the remaining SNPs the correlations ranged between .93 and .98. The lower  $r^2$  and correlations indicate that the quality of the imputation for rs726281 and rs3020407 was insufficient, and therefore only the directly genotyped data for these two SNPs were used. For the remaining six SNPs, the imputed genotypes were used. SNPtest calculates dosage data (ranging from 0 to 2) based on the

**TABLE 1. Haplotype frequency of the eight SNP *ESR1* haplotype and minor allele frequencies for three *ESR1* SNPs for patients with eating disorders, anorexia nervosa (restricting type), bulimia nervosa and controls including association analyses**

Haplotype	Control			Eating Disorders			Anorexia nervosa			Anorexia nervosa restricting type			Bulimia nervosa										
	DNA change	N	Freq	N	Freq	$\chi^2$	df	p	N	Freq	$\chi^2$	df	p	N	Freq	$\chi^2$	df	p					
AATTCGTC <sup>a</sup>	—	2780	0.22	514	0.21	0.98	1	0.32	241	0.22	0.11	1	0.75	140	0.25	1.48	1	0.22	141	0.21	0.11	1	0.74
rs726281	A>G	364	0.30	520	0.30	0.01	1	0.98	244	0.31	0.05	1	0.83	140	0.30	0.05	1	0.83	143	0.30	0.008	1	0.93
rs3798577	T>C	2708	0.47	519	0.48	0.05	1	0.82	244	0.50	1.30	1	0.25	140	0.48	0.004	1	0.95	142	0.44	1.44	1	0.23
rs2295193	T>C	2796	0.46	517	0.47	0.61	1	0.43	241	0.44	0.34	1	0.56	137	0.47	0.29	1	0.59	143	0.50	2.29	1	0.13

<sup>a</sup>rs726281\*A-rs3020407\*A-rs17081994\*T-rs2982712\*T-rs3020371\*C-rs2228480\*G-rs3798577\*T-rs2295193\*C

probabilities of the three possible genotypes for each SNP.<sup>14,15</sup> To take into account the uncertainty of the imputed genotype we applied the following thresholds on the dosage data: 0–0.10 for homozygotes of the common allele, 0.90–1.10 for heterozygotes, 1.90–2 for homozygotes of the minor allele.

### Statistical Analyses

The  $\chi^2$  test for Hardy–Weinberg equilibrium (HWE) was calculated in the controls using the HWE program of LINKUTIL (<http://linkage.rockefeller.edu/ott/linkutil.htm>). Power calculations were performed in Quanto version 1.2.4 (2009).

The haplotype frequency of the eight-SNP *ESR1* haplotype was compared in patients with an ED, patients with AN, patients with restricting type AN, patients with BN, and the control group, using Haploview (version 4.2). Furthermore, the allele frequencies of three SNPs (rs726281, rs2295193, and rs3798577) were compared between patient and control groups using Pearson's chi-square test (IBM-SPSS version 19).

## Results

In the control group none of the SNPs revealed a departure from HWE ( $p > .05$ ). This study had adequate power (85% power at  $\alpha$ -level 0.05, log-additive/allelic model) to detect effect sizes that were reported by Versini et al.<sup>7</sup> We had statistical power to detect effects sizes of at least 1.23 for EDs, between 1.33 and 1.45 for AN, and between 1.45 and 1.55 for restricting type AN and BN.

The results of the association analyses for the haplotype and the three single SNPs are shown in **Table 1**. There was no significant difference in the frequency of the eight-SNP *ESR1* haplotype (rs726281\*A-rs3020407\*A-rs17081994\*T-rs2982712\*T-rs3020371\*C-rs2228480\*G-rs3798577\*T-rs2295193\*C) which was overtransmitted in restricting type AN in the Versini study,<sup>7</sup> between controls (frequency 0.22) and patients with either an ED (frequency 0.21), BN (frequency 0.21), AN (frequency 0.22), or restricting type AN (frequency 0.25). There were no significant differences in minor allele frequency for rs726281, rs3798577, and rs2295193 between control women and patients with an ED, BN, AN, or restricting type AN.

## Discussion

This study aimed to replicate findings from a family-based association study that reported associations between AN and an eight-SNP *ESR1* haplotype, *ESR1* rs726281 and rs2295193, and an

association between rs3798577 and EDs.<sup>7</sup> Although the haplotype had a comparable frequency in our sample, it was not associated with either EDs, BN, AN, or restricting type AN. In addition, the frequency of none of the three *ESR1* SNPs differed between the groups. Altogether, we could not confirm the previous findings in the current study.

We had adequate statistical power to detect an effect ranging from 1.23 to 1.33 for ED, from 1.33 to 1.45 for AN, and from 1.45 to 1.55 for restricting type AN and BN. Given the ORs reported in the Versini study,<sup>7</sup> the power in the current study should have been sufficient to detect these effects. As there is a general tendency for initial studies to overestimate effect sizes, it is possible that associations were missed in the current study because of insufficient power to detect smaller effects. This could especially be the case for *ESR1* rs726281, for which a smaller number of control women were available due to the poorer quality of the imputation.

In the present study, the control groups were not screened for the absence or presence of an ED. Lifetime prevalence in women ranges between 0.9 and 3.5 for different types of EDs.<sup>1</sup> Because of this low prevalence only a small number of women will be affected in the population, of the total 2,810 controls approximately 165 could be affected. Additional analyses, not reported here, show that taking these possibly affected controls into consideration would not change our results.

From a biological perspective, the influence of estrogens on the development of EDs is plausible. There is some preliminary evidence that estradiol is a moderator of genetic effects on disordered eating during puberty.<sup>16</sup> Although it is still unclear whether estrogens are involved and what role they might play in EDs. The current study failed to replicate previously reported associations between the *ESR1* gene and AN.<sup>7</sup> To determine with certainty whether the *ESR1* gene is involved in the development of EDs larger future studies are required.

## References

- Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. *Biol Psychiatry* 2007;61:348–358.
- Hayward C, Killen JD, Gandy S, Taylor CB. Timing of puberty and the onset of psychiatric symptoms. *J Am Acad Child Adolesc Psychiatry* 1994;33:918–918.
- van Son GE, van HD, Bartelds AI, van Furth EF, Hoek HW. Time trends in the incidence of eating disorders: A primary care study in the Netherlands. *Int J Eat Disord* 2006;39:565–569.
- Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, et al. International Union of Pharmacology. LXIV. Estrogen receptors. *Pharmacol Rev* 2006;58:773–781.

5. Eckel LA. The ovarian hormone estradiol plays a crucial role in the control of food intake in females. *Physiol Behav* 2011;104:517–524.
6. Butera PC. Estradiol and the control of food intake. *Physiol Behav* 2010;99:175–180.
7. Versini A, Ramoz N, Le SY, Scherag S, Ehrlich S, Boni C, et al. Estrogen receptor 1 gene (ESR1) is associated with restrictive anorexia nervosa. *Neuropsychopharmacology* 2010;35:1818–1825.
8. Rosenkranz K, Hinney A, Ziegler A, Hermann H, Fichter M, Mayer H, et al. Systematic mutation screening of the estrogen receptor beta gene in probands of different weight extremes: Identification of several genetic variants. *J Clin Endocrinol Metab* 1998;83:4524–4527.
9. Eastwood H, Brown K M, Markovic D, Pieri LF. Variation in the ESR1 and ESR2 genes and genetic susceptibility to anorexia nervosa. *Mol Psychiatry* 2002;7:86–89.
10. Nilsson M, Naessen S, Dahlman I, Linden HA, Gustafsson JA, Dahlman-Wright K. Association of estrogen receptor beta gene polymorphisms with bulimic disease in women. *Mol Psychiatry* 2004;9:28–34.
11. Slof-Op 't Landt MC, Meulenbelt I, Bartels M, Suchiman E, Middeldorp CM, Houwing-Duistermaat JJ, et al. Association study in eating disorders: TPH2 associates with anorexia nervosa and self-induced vomiting. *Genes Brain Behav* 2011;10:236–243.
12. Van Beijsterveldt CE, Groen-Blokhuis M, Hottenga JJ, Franic S, Hudziak JJ, Lamb D, et al. The Young Netherlands Twin Register (YNTR): Longitudinal Twin and Family Studies in Over 70,000 Children. *Twin Res Hum Genet* 2013;16:252–267.
13. Willemsen G, Vink JM, Abdellaoui A, den BA, van Beek JH, Draisma HH, et al. The Adult Netherlands Twin Register: Twenty-five years of survey and biological data collection. *Twin Res Hum Genet* 2013;16:271–281.
14. Marchini J, Howie B. Genotype imputation for genome-wide association studies. *Nat Rev Genet* 2010;11:499–511.
15. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet* 2007;39:906–913.
16. Klump KL, Keel PK, Sisk C, Burt SA. Preliminary evidence that estradiol moderates genetic influences on disordered eating attitudes and behaviors during puberty. *Psychol Med* 2010;40:1745–1753.